Close
What would you like to look for?

9 January 2019

Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments in Lausanne, has successfully raised a further CHF 15.5 million in an extension of its Series B financing round bringing the total raised to CHF 35.5 million. The extension round was led by funds managed by Tekla Capital Management LLC and included Nan Fung Life Sciences, both new investors, as well as Oculis’ current investors.

The VISCHER-team advising Oculis is led by Matthias Staehelin (Partner) with Vincent Reardon (Senior Associate) and Vera Portmann (all Corporate).

Categories: Life Sciences, Pharma, Biotech, Mergers & Acquisitions, Private Equity & Venture Capital, Startup Desk, Deals & Cases

Authors